A retrospective analysis of adjuvant and neoadjuvant therapy in patients with resectable biliary tract adenocarcinoma shows they confer no survival advantage in the treated groups, leading the authors to conclude they have no benefit. However, the study design does not allow definitive conclusions to be drawn about these treatments.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
BMC Gastroenterology Open Access 12 April 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Glazer, E. S., Liu, P., Abdalla, E. K. Vauthey, J. N. & Curley, S. A. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J. Gastrointest. Surg. 16, 1666–1671 (2012).
Horgan, A. M., Amir, E., Walter, T. & Knox, J. J. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J. Clin. Oncol. 30, 1934–1940 (2012).
Neoptolomos, J. P. et al. Effect of adjuvant chemotherapy with fluoracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308, 147–156 (2012).
Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273–1281 (2010).
Jarnagin, W. R. et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables and clinical outcome. J. Clin. Oncol. 24, 1152–1160 (2006).
Rocha, F. et al. Intraductal papillary neoplasm of the bile duct (IPNB): a biliary equivalent to IPMN of the pancreas? Hepatology http://dx.doi.org/10.1002/hep.25786
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Jarnagin, W. Is there a role for neoadjuvant and adjuvant therapy in biliary cancer?. Nat Rev Gastroenterol Hepatol 9, 622–623 (2012). https://doi.org/10.1038/nrgastro.2012.186
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2012.186
